Surrozen, Inc./DE — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Surrozen announced plans to submit an IND for SZN-8141 by Q3 2026 and initiate the DUET Phase 1b/2a clinical trial in diabetic macular edema by year-end 2026, with initial data expected H2 2027. The U.S. PTAB denied Merck's post-grant review petition challenging patent claims. Q2 2026 cash was $102.0M (down $4.9M from Q1); the company reported $5.0M collaboration revenue (Boehringer Ingelheim milestone) and reported $50.2M net income driven by $59.6M non-cash gains on tranche and warrant liability revaluations.
Why this rating
Clinical trial initiation is routine biotech progress; $102M cash runway is adequate for pipeline. Non-cash gains mask $10.4M operating loss. PTAB win eliminates downside IP risk. Material for development trajectory but typical milestone, not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.